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Selective cognitive and psychiatric manifestations
in Wolfram Syndrome
Allison N. Bischoff1, Angela M. Reiersen1, Anna Buttlaire1, Amal Al-lozi1, Tasha Doty1, Bess A. Marshall2,3,
Tamara Hershey1,4,5* and Washington University Wolfram Syndrome Research Group
Abstract
Background: Wolfram Syndrome (WFS) is known to involve diabetes mellitus, diabetes insipidus, optic nerve
atrophy, vision loss, hearing impairment, motor abnormalities, and neurodegeneration, but has been less clearly
linked to cognitive, sleep, and psychiatric abnormalities. We sought to determine whether these abnormalities are
present in children, adolescents, and young adults with WFS compared to age- and gender-matched individuals
with and without type 1 diabetes using standardized measures.
Methods: Individuals with genetically-confirmed WFS (n = 19, ages 7–27) were compared to age- and gender- equivalent
groups of individuals with type 1 diabetes (T1DM; n = 25), and non-diabetic healthy controls (HC: n = 25).
Cognitive performance across multiple domains (verbal intelligence, spatial reasoning, memory, attention, smell
identification) was assessed using standardized tests. Standardized self- and parent-report questionnaires on
psychiatric symptoms and sleep disturbances were acquired from all groups and an unstructured psychiatric
interview was performed within only the WFS group.
Results: The three groups were similar demographically (age, gender, ethnicity, parental IQ). WFS and T1DM
had similar duration of diabetes but T1DM had higher HbA1C levels than WFS and as expected both groups had
higher levels than HC. The WFS group was impaired on smell identification and reported sleep quality, but was
not impaired in any other cognitive or self-reported psychiatric domain. In fact, the WFS group performed better than the
other two groups on selected memory and attention tasks. However, based upon a clinical evaluation of only
WFS patients, we found that psychiatric and behavioral problems were present and consisted primarily of anxiety
and hypersomnolence.
Conclusions: This study found that cognitive performance and psychological health were relatively preserved WFS
patients, while smell and sleep abnormalities manifested in many of the WFS patients. These findings contradict past
case and retrospective reports indicating significant cognitive and psychiatric impairment in WFS. While many of these
patients were diagnosed with anxiety and hypersomnolence, self-reported measures of psychiatric symptoms indicated
that the symptoms were not of grave concern to the patients. It may be that cognitive and psychiatric issues become
more prominent later in life and/or in later stages of the disease, but this requires standardized assessment and larger
samples to determine. In the relatively early stages of WFS, smell and sleep-related symptoms may be useful biomarkers
of disease and should be monitored longitudinally to determine if they are good markers of progression as well.
Trial Registration: Current Clinicaltrials.gov Trial NCT02455414.
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Background
Wolfram Syndrome (WFS) (OMIM #222300) [1] is a
rare autosomal recessive disease typically characterized
by diabetes mellitus, diabetes insipidus, optic nerve at-
rophy, hearing and vision loss, motor impairment, neu-
rodegeneration, and a reduced lifespan. WFS can be
caused by mutations in the WFS1 gene, which is known
to encode the wolframin protein. Wolframin exists
within the endoplasmic reticulum (ER) membrane [2]
and helps to protect cells from ER stress related apop-
tosis [3–5]. Wolframin deficiency leads to cell death in
the insulin producing β-cells in the pancreas, causing
diabetes, and is also thought to underlie cell death in
the brain [6]. As cellular studies move towards possible
clinical interventions [7], an understanding of the nat-
ural history of WFS is becoming more critical, and the
progressive neurological aspects of WFS, including
brain structure abnormalities, gait impairment, and
cognitive and behavioral difficulties, are receiving in-
creasing attention [8–10].
Recent work has shown that altered brain structure
in the brainstem and cerebellum can be detected early
in the disease process through in vivo neuroimaging [8].
Clinical retrospective data and case studies have sug-
gested that neurological symptoms, such as ataxia and
cognitive changes, occur from teenage years into mid-
adulthood [11, 12], yet our direct measurements [9]
found that motor neurological abnormalities, such as
poor balance and altered gait, are present in childhood
and early adolescence. It is unknown at this point
whether non-motor, complex, and higher order neuro-
logical functions, such as cognition and emotional
functions, also follow this pattern, or if those functions
are relatively spared early in the disease due to their in-
dependence from brainstem and cerebellum function.
However, these domains have been poorly quantified in
previous studies. While several case studies reported
cognitive impairment and depression in adult patients
with advanced WFS [12–16], others described patients
with normal intelligence [17, 18]. Studies typically have
lacked standardized testing or an age-matched control
group for comparison.
Our group has studied a cohort of children, adolescents,
and young adults with WFS using standardized and quanti-
fied assessments of cognitive, psychiatric, and behavioral
abnormalities. We also acquired overlapping measures on
age- and gender-matched individuals with and without type
1 diabetes mellitus (T1DM). The goal of this paper is to de-
scribe the nature and extent of non-motor abnormalities in
a deeply phenotyped cohort of young patients with
genetically-confirmed WFS. This information may reveal
biomarkers for disease progression, targets for symptomatic





WFS patients were identified through the Washington
University International Wolfram Syndrome Registry
and were participants in a longitudinal natural history
study (Washington University Wolfram Syndrome Re-
search Clinic) involving annual data collection over
5 years. For enrollment in the Research Clinic, patients
had to be age 30 or younger and have genetically con-
firmed WFS (mutations of the WFS1 gene), or diabetes
mellitus and optic atrophy diagnoses before age 18.
Subsets of these data have been analyzed to answer
other questions [8, 10]. For this paper, we analyzed data
from the 2013 clinic because that year’s clinic used a
wider variety of cognitive, psychiatric, and behavioral
measures and had a larger and more diverse patient
sample than previous years.
Controls
The comparison groups consisted of individuals with
type 1 diabetes (T1DM) and non-diabetic healthy con-
trols (HC). The T1DM group was recruited through
Washington University’s Pediatric Diabetes Clinic at St.
Louis Children’s Hospital and Washington University
School of Medicine in St. Louis. All T1DM were clinic-
ally diagnosed with T1DM based on disease presenta-
tion, physical exam, medical history, and family history.
T2DM and monogenic DM were ruled out based on
physical exam and personal and family history based on
the guidelines established by the American Diabetes
Association. The HC group was recruited through the
community, or were siblings of participants in the
T1DM group. Exclusion criteria included self-reported
psychiatric or neurological diagnoses, the use of psycho-
active medications, contraindication to MRI, and <36 week
gestation with respirator use or other complications.
The study was approved by the Human Research Pro-
tection Office at Washington University in St. Louis.
Informed consent was obtained prior to testing for all
participants. For children under age 18, parents/guard-
ians provided written consent and children assented to
testing.
Assessments
WFS patients performed cognitive, psychiatric, smell,
and behavioral assessments, including parent-report of
symptoms. In addition, HbA1c and capillary glucose
levels were measured and a medication log was ac-
quired. These measures and the resulting data are pre-
sented in this paper. WFS patients also performed
vision, auditory, neurological, taste, endocrinologic, and
urologic assessments (data not presented). All tests
were performed over a 3 day period in July 2013.
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Controls performed all of the tests described below,
with the exception of the WURS and an unstructured
psychiatric interview, on a single day, spread through-
out two years.
WURS
A neurologist completed the Wolfram Unified Rating
Scale (WURS) [19] during the clinic on each WFS pa-
tient. The WURS was designed to assess overall disease
progression and severity of physical and behavioral issues
previously observed in WFS (e.g. vision, hearing, motor,
urological, neurological, psychological and mood prob-
lems) and has been shown to have good inter-rater reli-
ability and validity [19]. The Total WURS score is
made up of Physical (maximum score = 160) and Be-
havioral (maximum score = 54) subscales.
Cognitive testing
Capillary glucose levels were checked prior to testing
for all subjects; testing proceeded once levels were de-
termined to be between 70 and 300 mg/dl.
1) Wechsler Abbreviated Scale of Intelligence
Vocabulary and Similarities subtests (ages 6+) [20]:
These subtests were used to generate a verbal
intelligence quotient (VIQ).
2) Woodcock-Johnson III Spatial Relations (SR) subtest
(all ages) [21] was used to assess spatial reasoning;
scaled scores were generated.
3) Letter-Number Sequencing (LNS) and Digit Span
(DS) subtests were used to measure short-term/
working memory. These subtests came from the
Wechsler Intelligence Scale for Children (ages 6–15)
[22] or the Wechsler Adult Intelligence Scale (16+)
[23] and generated scaled scores.
4) California Verbal Learning Test (CVLT-C for ages
0–15 [24] and CVLT-II for ages 16+ [25]) was used
to assess verbal learning and delayed memory.
Short-term and long-term delay scaled scores were
used in analyses.
5) Conner’s Continuous Performance Task (CPT) (ages
6+) [26] is a computerized assessment of sustained
attention and impulsivity. Hit Reaction Time and
Detectability scaled scores were used in analyses.
6) University of Pennsylvania’s Smell Identification Test
(UPSIT) (ages 5+) [27] was used to measure smell
identification skills and raw scores were calculated.
7) Wechsler Test of Adult Reading (WTAR) [28] was
used to measure a parent’s verbal intelligence and
scaled scores were generated.
Psychiatric and behavioral interview and measures
WFS patients and their parents, as appropriate, met with
a study psychiatrist to discuss current psychoactive
medication use, past diagnoses, and psychiatric question-
naires completed for the clinic. The study psychiatrist,
based upon past report and clinical impression, assigned a
“best estimate diagnosis” to each patient. The WFS group
and control groups and parents/caregivers of subjects
under age 18 completed psychiatric and behavioral
questionnaires.
1) Child and Adolescent Symptom Inventory 4R
(CASI-4R) (given to WFS of all ages and controls
ages 5–17) [29] is a parent-reported inventory that
itemizes DSM-IV relevant symptoms of behavioral
and emotional disorders.
2) Adult Self-Report Inventory-4 (ASRI-4) (ages 18+)
[30] and Youth Inventory-4 (YI-4R) (ages 12–17)
[31] are adult- and youth-reported inventories that
itemize DSM-IV relevant symptoms of behavioral
and emotional disorders. These inventories generate
scores for a variety of symptom categories that
can be assessed using the Symptom Count Score
method. The Symptom Count Score method
evaluates symptom frequency (never, sometimes,
often, and very often) and determines if the
number of symptoms above a threshold frequency
meets the symptom criterion for a specific disorder.
We focus here on the symptom categories that were
the same across ages and reports (parent, adult, youth),
namely: ADHD-Inattentive, ADHD-Hyperactive-
impulsive, Conduct Disorder, Oppositional Defiant
Disorder (ODD), General Anxiety, Social Phobia,
Specific Phobia, Obsessions, Compulsions, Major
Depressive Episode (MDE), Manic episodes (Bipolar
Disorder), and Dysthymia. To note, for the Specific
Phobia, Obsessions, and Compulsions categories, the
CASI-4R parent-report requires a lower frequency of
symptoms to meet criterion compared to the self-
reported inventories (i.e., reported frequency must be
“sometimes”, rather than “often” or “very often”).
Furthermore, only 1 question was included in the
criterion score for these categories, whereas other
categories had multiple questions within the criterion
score. Meeting symptom criterion cutoff did not imply
a diagnosis (other criteria such as age-of-onset, duration,
impairment, and exclusion criteria were not fully
assessed by the instrument), but indicated a particular
subject endorsed experiencing a threshold number of
symptoms that may indicate a particular diagnosis.
3) Pediatric Sleep Questionnaire (PSQ) (given to WFS
of all ages and controls ages 0–17) [32] and
Pittsburgh Sleep Quality Index (PSQI) (ages 18+)
[33] were parent- and adult self-reports used to
evaluate sleep dysfunction. A raw score above 0.33
on the PSQ and a raw score above 5 on the PSQI
suggest clinically diagnosable sleep problems.
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Statistical analysis
All of the data was managed using REDCap, a web-based
electronic database hosted by the Biostatistics Division of
Washington University School of Medicine [34]. Data was
analyzed using the statistical program SPSS©.
Participant characteristics
Age, gender, diabetes duration, HbA1c, and glucose levels
were compared across groups (WFS, T1DM, HC) using
univariate general linear models (GLMs) or chi-square
tests. Significant main effects of group (p < 0.05) were
followed by post-hoc comparisons.
Cognitive tests
Cognitive variables were compared across groups using
GLMs. All cognitive variables except for the UPSIT raw
scores were scaled scores, t-scores, or z-scores that pro-
vided adjustment for age and, in a subset of variables,
for gender. For those scores that did not correct for gen-
der (WTAR, VIQ, LNS, DS), gender was co-varied in
analyses. UPSIT raw scores were co-varied for both age
and gender. UPSIT percentile scores were not used for
analysis due to limited available normative data in young
ages. Significant main effects of group (p < 0.05) were
followed by post-hoc comparisons.
Psychiatric and behavioral measures
For the psychiatric inventories, we focused our analysis
on three major domains (Neuro-developmental and
Disruptive Behavior, Anxiety Disorders, and Mood Disor-
ders) that comprised the symptom categories previously
mentioned. Neuro-developmental and Disruptive Behavior
included ADHD-Inattentive, ADHD-Hyperactive-impulsive,
Conduct Disorder, and ODD. Anxiety Disorders in-
cluded General Anxiety, Social Phobia, Specific Phobia,
Obsessions, and Compulsions. Mood Disorders included
Major Depressive Episode, Manic Episodes (Bipolar
Disorder), and Dysthymia. We combined overlapping
adult-reported and youth-reported domain scores into
a ‘self-report’ domain to reduce comparisons and increase
sample size. We scored 12-year-olds in the 12–18 year
range rather than the 5–12 year range. Chi-square tests
were used to compare the proportion of individuals that
reached the symptom criterion cutoff for one or more
symptom category within each domain. Parent-report and
self-report cutoffs were separately determined. PSQ scores
were compared across groups using GLMs, co-varied for
age and gender. PSQI scores were not used for analysis due
to small sample size of adult participants. Significant main
effects of group (p < 0.05) were followed by post-hoc
comparisons.
Correlations
Pearson or Spearman correlations were performed be-
tween variables that were significantly impaired in the
WFS group compared to controls and indictors of WFS




We evaluated 19 genetically-confirmed WFS patients, 25
individuals with T1DM and 25 individuals without
T1DM. Demographic data are shown in Table 1. Eight
WFS participants had participated in the clinic for 3 pre-
vious years; 3 had participated in 2 previous years; 4 had
participated in 1 previous year and 4 were participating
in the clinic for the first time. Four WFS patients were
non-English speaking and only completed the spatial
reasoning and smell identification tasks. All participants
in the control groups were native English speakers. Two
WFS patients were severely vision impaired and could
not complete the SR or CPT tasks. One WFS patient
was severely hearing impaired and could not complete
the WASI, LNS, DS, or CVLT tasks. Two other WFS
Table 1 Participant characteristics
WFS T1DM HC
N 19 25 25
Gender distribution 13 F, 6 M 15 F, 10 M 10 F, 15 M
Ethnicity distribution (%) 84.2 C, 10.5 H, 5.3 O 92 C, 4 AA, 4 H 72 C, 8 AA, 8 H, 12 O
Mean (SD) p
Age 15.8 (6.0) 13.6 (4.6) 14.3 (5.6) 0.43
Diabetes duration 10.2 (5.9) 7.6 (5.0) –– 0.13
HbA1c (%) 7.5 (1.2)
b 8.3 (1.0)a,b 5.3 (0.3) <0.001*
Capillary glucose (mg/dl) 196.5 (60.5) b 209.5 (73.2)b 93.5 (11.8) <0.001*
C Caucasian, AA African American, H Hispanic, O other
*significant at p < 0.05; p values shown for the main effect of group in univariate GLM analyses for each measure
amean different from WFS group
bmean different from HC group
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patients were assessed, but their data were excluded for
analysis. One patient experienced a neurological trauma
(anoxic event) in early childhood that may have affected
cognition, and the other was a very young, non-English
speaking patient who was unable to complete cognitive
tasks.
The WFS and control groups did not differ in age
(F2, 66 = 0.86, p = 0.43), gender (χ
2 (N = 69) = 3.91, p = 0.14),
or diabetes duration (T1DM vs WFS; F1, 41 = 2.40, p = 0.13),
even when subsamples (e.g. for variables with some missing
data) were considered. However, there was a main effect of
group on HbA1c (F2, 62 = 68.43, p < 0.001), with all three
groups differing from each other (p < 0.01). There was also
a main effect of group on glucose levels (F2, 64 = 32.57,
p < 0.001), with HC having lower levels than both WFS
(p < 0.001) and T1DM (p < 0.001); WFS and T1DM did
not differ from each other. However, no glucose level
was obtained at time of testing for 2 WFS patients.
One of these patients does not have diabetes (Fasting
glucose = 86 mg/dl). See Table 1.
WFS clinical characteristics
Table 2 reports age of diabetes mellitus onset, age of
optic atrophy diagnosis, and WFS1 allele mutations. Age
of optic atrophy diagnosis may not reflect true age of
onset. Eighteen WFS patients had insulin dependent dia-
betes mellitus and 15 had diabetes insipidus. Eighteen
WFS patients had optic atrophy and 12 had hearing loss.
WFS patients’ WURS Physical total scores ranged from
0 to 33 (M = 10.4, SD = 8.8). WURS Behavioral total
scores ranged from 0 to 15 (M = 5.8, SD = 4.7). WURS
Total scores ranged from 5 to 44 (M = 15.8, SD = 11.6).
Cognitive assessments
Table 3 reports group means and standard errors for
each cognitive variable analyzed.
Parent IQ estimate
The average parent WTAR verbal intelligence score did
not differ across groups (F2, 49 = 1.31, p = 0.28).
Verbal and spatial intelligence
There was no main effect of group for VIQ (F2, 59 = 0.36,
p = 0.70) or SR standard score (F2, 64 = 2.63, p = 0.08).
On a trend level, HC performed better on SR than
T1DM. WFS did not differ from either T1DM or HC.
Memory
Groups differed at a trend level on LNS (F2, 59 = 2.94,
p = 0.06; T1DM >WFS > HC), but did not differ on DS
(F2, 57 = 1.33, p = 0.27). Groups also differed at a trend
level on CVLT short-term memory (F2, 58 = 2.72, p = 0.07;
WFS >T1DM>HC). In addition, there was a main effect
of group on CVLT long-term memory (F2, 58 = 4.01,
p = 0.02), with the WFS group performing better (remem-
bering more words after a 20 min delay) compared to both
the T1DM (p = 0.02) and HC groups (p = 0.01).
Attention and impulsivity
Groups did not differ on CPT Hit Reaction Time
(F2, 60 = 1.33, p = 0.27). However, there was a main effect of
group on CPT Detectability (F2, 60 = 3.15, p = 0.05) with the
WFS group showing better attentiveness and lower rates of
impulsivity compared to the T1DM group (p = 0.02), but
not to HC group (p = 0.12).
Smell identification
Groups differed on UPSIT raw score (F2, 63 = 9.38,
p < 0.001), with the WFS group scoring lower than
both the T1DM (p < 0.001) and HC groups (p < 0.001)
(Fig. 1). Upon reviewing the UPSIT raw score data, we
identified 3 older WFS patients that were much more
impaired than other patients. We analyzed the data






WFS mutation allele 1 WFS mutation allele 2
































6 7 c.817G>T; P.E273X c.1839G>A; p.W613X
6 9 c.2648del4; p.F883fs None identified
7 7 c.320G>A; p.G107E c.1882C>T; p.R629W
7 8 c.376G>A; p.A126T c.1838G>A;p.W613X





14 12 c.605A>G; p.E202G c.631G>A; p.D211N
No dx 5 c.2339G>C,
p.Gly780Ala
c.2452C>T, p.Arg818Cys
DM diabetes mellitus, OA optic atrophy, No dx No diagnosis in 2013
Bischoff et al. Orphanet Journal of Rare Diseases  (2015) 10:66 Page 5 of 11
excluding these 3 WFS patients and still found group
differences (F2, 60 = 7.52, p < 0.001), with the WFS
group scoring lower than the T1DM (p < 0.001) and
HC (p < 0.001) groups.
Psychiatric and behavioral interview and assessments
Psychiatric interview
Nineteen WFS patients completed a psychiatric inter-
view. Four WFS patients were currently prescribed psy-
choactive medications. Three patients were prescribed
SSRIs (duloxetine, fluoxetine, sertraline) for anxiety and/
or depression, and 1 of those patients was also pre-
scribed lisdexamfetamine and atomoxetine for ADHD.
The patient on fluoxetine was also taking risperidone for
bipolar disorder. One patient was only taking lorazepam,
a benzodiazepine, for anxiety symptoms. Three WFS pa-
tients reported a previous psychiatric diagnosis (diagno-
ses included: Generalized Anxiety, Major Depressive
Disorder, ADHD, OCD, Bipolar Disorder), and 2 WFS
patients reported undiagnosed symptoms, including anx-
iety, depression, and OCD. Four WFS patients were clas-
sified as having no psychiatric disorder by the study
psychiatrist. One WFS patient was not fully evaluated
due to incomplete psychiatric inventory questionnaires.
The study psychiatrist assigned 10 patients a “best esti-
mate diagnosis” of Unspecified Anxiety Disorder. Of
those 10 patients, six received a co-morbid diagnosis of
at least one other disorder, including Autism Spectrum
Disorder, Major Depressive Disorder, ODD, OCD, and/
or ADHD. Six WFS patients (patients were 13 years old
or older) received a diagnosis of Hypersomnolence Dis-
order, and all of these patients had at least one other
diagnosis. Other “best estimate diagnoses” occurring in
those without a diagnosis of Unspecified Anxiety Dis-
order included a diagnosis of Unspecified Bipolar Dis-
order (n = 1), Separation Anxiety (n = 1), and Specific
Phobia (n = 1).
Psychiatric inventories
Of the 19 WFS patients who were clinically assessed, 12
WFS, 21 T1DM, and 20 HC completed the parent-
reported CASI-4R. Eight WFS, 13 T1DM, and 16 HC com-
pleted self-reports. The psychiatric inventory data only
included English-speaking WFS patients. Four WFS pa-
tients were missing at least one parent or self-report instru-
ment. Two of these patients did not have either report.
One HC participant was not included because age was out-
side the age range for both the CASI-4R and YI-4R.
Neuro-developmental and disruptive behavior disorders
16.7 % WFS, 4.8 % T1DM, and 5.0 % HC met criteria for
one or more neuro-developmental or disruptive behavior
Fig. 1 UPSIT raw score differed across groups after correcting for
age and gender (F2, 63 = 9.38, ***p < 0.001). The WFS group
performed significantly worse on the UPSIT than the T1DM group (p
< 0.001) or the HC group (p < 0.001)
Table 3 Cognitive assessment adjusted means (±S.E.)
Normative average WFS T1DM HC p
N M N M N M
WTAR scaled scorec 100 14 104.1 ± 2.5 21 105.3 ± 2.0 18 109.2 ± 2.2 0.28
VIQc 100 14 111.8 ± 3.5 25 108.2 ± 2.6 24 108.8 ± 2.7 0.70
Spatial relations scaled scorec 100 17 107.1 ± 2.3 25 104.6 ± 1.9 25 110.7 ± 1.9 0.08
L-N sequencing scaled scorec 10 14 11.1 ± 0.7 25 12.1 ± 0.6 24 10.2 ± 0.6 0.06
Digit span scaled scorec 10 14 12.1 ± 0.9 25 10.9 ± 0.7 22 12.4 ± 0.7 0.27
CVLT short delay recall z-scorec 0 14 0.6 ± 0.2 23 0.1 ± 0.2 24 −0.1 ± 0.2 0.07
CVLT long delay recall z-scorec 0 14 0.7 ± 0.2a,b 23 0.0 ± 0.2 24 −0.1 ± 0.2 0.02*
CPT hit reaction t-scored 50 13 39.2 ± 2.5 25 38.8 ± 1.8 25 42.8 ± 1.8 0.27
CPT detectability t-scored 50 13 48.1 ± 2.7b 25 56.3 ± 1.9 25 53.3 ± 1.9 0.05*
UPSIT raw scoresc 35+ 19 23.6 ± 1.4a,b 25 31.0 ± 1.2 24 30.1 ± 1.2 <0.001*
p values shown for the main effect of group in univariate GLM analyses for each measure after correcting for age and gender
*significant at p < 0.05
adifferent from HC group
bdifferent from T1DM group
chigher average = better performance
dlower average = better performance
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disorder on the parent-report. 7.7 % T1DM and 12.5 % HC
met criteria on the self-report. None of the WFS patients
self-endorsed having neuro-developmental or disrup-
tive behavior symptoms above threshold. Groups did
not differ on how likely they were to meet the criteria
for a neuro-developmental or disruptive behavior dis-
order on the parent- or self-report (χ2 (N = 53) = 1.85,
p = 0.40; (χ2 (N = 37) = 1.12, p = 0.57).
Anxiety disorders
50.0 % WFS, 38.1 % T1DM, and 30.0 % HC met criteria for
one or more anxiety disorder on the parent-report. 12.5 %
WFS, 15.4 % T1DM and 25.0 % HC met criteria on the
self-report. Groups did not differ on how likely they were
to meet the criteria for an anxiety disorder on the parent-
or self-report (χ2 (N = 53) = 1.28, p = 0.52; (χ2 (N = 37) =
0.71, p = 0.70).
Mood disorders
8.3 % WFS, 4.8 % T1DM, and 0 % HC met criteria for one
or more mood disorder on the parent-report. 12.5 % WFS,
7.7 % T1DM, and 6.3 % HC met criteria on the self-report.
Groups did not differ on how likely they were to meet the
criteria for a mood disorder on the parent- or self-report
(χ2 (N = 53) = 1.52, p = 0.47; (χ2 (N = 37) = 0.28, p = 0.87).
Sleep questionnaires
Table 4 reports group means and standard errors for the
PSQ measure. There was a main effect of group on the
parent-reported PSQ total score (F2, 49 = 7.55, p < 0.001),
with more symptoms reported for the WFS group than the
T1DM (p = 0.02) and HC groups (p < 0.001). Groups also
differed on the PSQ sleepiness subscore (F2, 49 = 4.98,
p = 0.01), again with the WFS group having more
symptoms than the other two groups (T1DM, p = 0.03;
HC, p = 0.01). Groups did not differ in either the PSQ
snoring (F2, 49 = 0.49, p = 0.62) or PSQ behavior (F2, 49 =
1.91, p = 0.16) subscores. Groups did differ in how likely
they were to fall in the ‘at-risk for sleep problems’ range on
the PSQ sleepiness score (χ2 (N = 54) = 12.63, p < 0.01; 71 %
WFS, 24 % T1DM, 16 % HC), but not in the PSQ total
score (χ2 (N = 54) = 1.82, p = 0.40; 7 % WFS, 10 % T1DM,
0 % HC), PSQ snoring score (χ2 (N = 54) = 1.82,
p = 0.40; 7 % WFS, 10 % T1DM, 0 % HC), or PSQ be-
havior score (χ2 (N = 54) = 3.26, p = 0.20; 0 % WFS,
10 % T1DM, 0 % HC).
In a separate analysis of PSQ total score, older WFS pa-
tients were removed in order to reflect the age range
intended for this questionnaire. Groups still differed on
PSQ total score (F2, 46 = 9.11, p < 0.001), with the WFS
group reporting more symptoms than the T1DM (p = 0.04)
and HC groups (p < 0.001).
Correlations
Within the WFS group, UPSIT raw scores correlated
with WFS diabetes duration (r = −0.56, p = 0.02) such
that longer duration was associated with lower smell
identification performance (Fig. 2). UPSIT raw scores
did not correlate with age or the WURS total or subscale
scores. All other variables that were different across
groups (CVLT long-delay recall, CPT Detectability, PSQ
total score, PSQ sleepiness) did not correlate with
WURS or diabetes duration.
Discussion
The purpose of this study was to determine whether
there are any cognitive or psychiatric symptoms in rela-
tively early stage WFS. This study advances the literature
by directly assessing both WFS patients and age- and
gender-matched control groups with standardized, quan-
titative assessments. Overall, we found selective deficits
in WFS patients in smell identification and sleep distur-
bances, but no impairment in cognitive performance.
Based upon a clinical evaluation of WFS patients only,
we found that psychiatric and behavioral problems were
present and consisted primarily of anxiety and hyper-
somnolence. However, when self- and parent-reported
psychiatric symptom inventories were compared to con-
trol groups, there was no difference in rates of these re-
ported symptoms. Smell identification deficits were
associated with diabetes duration, but there were no
other relationships between proxies of disease severity
Table 4 Sleep measures adjusted means (±S.E.)
Normative average WFS T1DM HC p
N M N M N M
PSQ total scorec 14 0.21 ± 0.0a,b 21 0.12 ± 0.0 19 0.06 ± 0.0 <0.001*
PSQ sleepinessc 14 0.48 ± 0.1a,b 21 0.21 ± 0.01 19 0.16 ± 0.1 0.01*
PSQ snoringc 14 0.12 ± 0.1 21 0.10 ± 0.0 19 0.05 ± 0.1 0.62
PSQ behaviorc 14 0.07 ± 0.0 21 0.10 ± 0.0 19 0.03 ± 0.0 0.16
p values shown for the main effect of group in univariate GLM analyses for each measure after correcting for age and gender
*significant at p < 0.05
adifferent from HC group
bdifferent from T1DM group
clower average = better sleep
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and assessment results. These results indicate that in
relatively early stage WFS, smell tests and sleep ques-
tionnaires distinguish WFS from control groups better
than cognitive tests or self- or parent-reported psychi-
atric questionnaires. However, psychiatric interviews of
WFS patients suggest that there are diagnosable psychi-
atric conditions that in some cases are well-managed
with pharmacological treatment. Although it is not clear
if the rate of diagnosable psychiatric conditions in WFS
differ from control groups from this study, longitudinal
interview data in our WFS cohort may determine if psychi-
atric diagnoses are a useful index of disease progression.
Past studies have reported either cognitive impairment
(learning difficulties, memory issues, decreased verbal
performance) [12–15] or normal cognitive development
in WFS patients [17, 18]. However, many of these studies
were case reports without quantitative data on cognitive
measures, had very small sample sizes, or were based on
clinical impressions of older, more affected patients. In
contrast, using structured testing and age- and gender-
matched control groups, we found that WFS patients
perform similarly to and in some cases better than con-
trols, suggesting that cognitive impairment is not an
early or prominent feature of WFS. It is possible, how-
ever, that cognitive impairment may evolve in the later
stages of the disease. Interestingly, the WFS group per-
formed better on a few tests, which could be due to
higher motivation, perhaps to compensate for hearing or
vision loss, or because of practice effects, as some had
performed these tests in previous years. However, we
found that a smaller subset of these WFS patients per-
formed within or above the average range for verbal
intelligence, memory, and attention on their first year of
clinic [8], suggesting that even without practice they are
performing well. The issues of practice effects or later
degeneration of higher order cognitive function are best
addressed with longitudinal data from both WFS and
controls.
Similar to the cognitive data, our psychiatric and behav-
ioral data yielded results somewhat inconsistent with past
literature. Previous reports have indicated that there may
be a role of the WFS1 gene in depression and suicide at-
tempts [35, 36], as carriers of one WFS1 mutation had a
greater risk for lifetime psychiatric symptoms. Studies of
WFS patients have also suggested that WFS patients suffer
from high rates of depression and anxiety [14, 15, 37].
However, these reports were based on overall clinical im-
pressions and self-report of diagnoses rather than standard-
ized measures or structured clinical interviews and lacked
appropriate control groups. Notably, during a clinical inter-
view with the study psychiatrist, many of the WFS patients
reported previous symptoms consistent with an Unspeci-
fied Anxiety Disorder. However, in more than one case, the
study psychiatrist noted that the patient’s parent was very
concerned about the patient’s anxiety and psychiatric symp-
toms, but the patient did not agree they had significant
symptoms. There is a possibility that this could be influ-
enced by parental anxiety about their child’s symptoms, or
it could be due to limited insight of the patient. Further-
more, we did not find elevated psychiatric symptoms in the
standardized parent- or self-report of current symptoms in
three critical psychiatric domains—Neuro-developmental
and Disruptive Behavior, Anxiety, and Mood disorders—as
compared to the control groups. The apparent incongruity
of results between our findings and previous reports could
indicate: (1) younger WFS patients may not experience the
same severity of psychiatric issues as older, more impaired
WFS patients; (2) that our patients have received appropri-
ate support and treatment for their symptoms; or (3) these





















Relationship between Diabetes Duration and UPSIT Raw
Scores
Fig. 2 There was a significant relationship between diabetes duration and UPSIT raw scores in the WFS group (r = −0.56, p = 0.02), indicating that
smell identification decreased with increased exposure to diabetes
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symptoms for this particular cohort of patients. Never-
theless, the psychiatric symptoms the WFS patients
may experience are generally treatable and manageable
as indicated by the lack of self-reported symptoms.
Consistent with past reports [17, 15, 38, 39], we saw
selective deficits in WFS patients in smell identification.
Olfactory dysfunction often is an early indicator of neu-
rodegenerative diseases, such as multiple sclerosis (MS),
Parkinson’s disease, and Alzheimer’s disease [40]. Several
WFS studies have reported a range of olfactory issues in
patients, including anosmia [17, 15, 38, 39]. However,
these studies did not detail how they assessed patients,
did not include control groups, and were primarily case
reports of older adults. Our results indicate that smell
identification deficits are present early in WFS, even
compared to a T1DM control group, and are not explained
by differences in cognitive function. Further, since smell
deficits were worse in those with greater duration of dia-
betes, it is possible that smell may be a potential marker of
disease progress; however, this hypothesis will need longitu-
dinal data to confirm.
Sleep dysfunction was also common in our WFS
group. WFS patients and their parents reported more
sleep-related problems, such as snoring, heavy breath-
ing, bed wetting, and sleepiness than controls. Further-
more, the study psychiatrist found that the majority of
adolescent and adult (6/10 patients ≥ 13 years of age)
WFS patients qualified for hypersomnolence disorder.
It is unclear whether these sleep problems are central
to WFS or due to the presence of a chronic disease like
type 1 diabetes or diabetes insipidus, which can in-
crease the frequency of nocturnal urination and sleep
disruption. Sleep problems are prevalent among indi-
viduals with type 1 diabetes [41–43]. Matyka et al.
found that compared to unaffected children, children
with T1DM woke up more during the night and slept
less. However, our T1DM and control groups did not
differ in sleep problems, so it is unlikely that diabetes
per se explains sleep problems in our WFS sample.
Sleep studies using actigraphy to record motion and
pulse oximetry to monitor respiration could help dis-
tinguish between the mitigating clinical and environ-
mental factors altering sleep behavior in WFS and
possible underlying neurologic dysfunction. Given that
death due to WFS has been ascribed to sleep apnea in
some cases [11], these features deserve closer attention
and evidence-based intervention.
The pattern of spared and affected non-motor
neurological function that we describe in this paper is
generally consistent with the known pattern of struc-
tural brain abnormalities in WFS. We have observed
striking brain volume differences in lower brain order
systems like the brainstem and cerebellum in WFS (in-
cluding some of the patients represented in this
paper), but few differences in cortical volume mea-
surements [8]. Smell and sleep are mediated by com-
plex interactions between the brain stem, limbic system,
hypothalamus, and some cortical regions [40, 44, 45],
whereas cognitive function relies primarily on higher order
cortical networks. Further cross-sectional and longitudinal
structure-function analyses will be necessary to determine
whether these relationships exist in WFS.
Our study was a thorough examination of the cognitive,
psychiatric, and behavioral outcomes seen in WFS. The
major strengths of the study are the inclusion of an age-
and gender-matched control group and the use of stan-
dardized measures. However, there were some limitations
to the study. First, although our WFS group and control
groups performed similarly on the cognitive tasks, we may
have selected a WFS cohort that was a high functioning
group with access to more resources than the average
WFS family. However, a wide range of symptom severity
was represented in our WFS group, suggesting that they
were not high functioning in all domains. Also, this may
be a function of the wide age range in our WFS patients,
from early childhood to early adulthood. This age range
could also obscure the possibility that psychiatric symp-
toms and diagnoses are a later emerging issue in WFS. Al-
though we saw no obvious relationship between age and
symptoms, aside from a possibly higher rate of hypersom-
nolence in adolescence and adulthood, our sample is likely
too small to detect such a pattern. Second, some of our
WFS patients were exposed to the testing measures in
previous clinics, while the control groups had not been ex-
posed. However, regardless of practice, our WFS patients
still showed significant impairments in smell identifica-
tion. Third, the WFS group and control groups did not re-
ceive the same psychiatric evaluation, and the control
group was screened for psychiatric diagnoses and medica-
tion use prior to study enrollment. Four WFS patients
were currently prescribed psychoactive medication for
psychiatric symptoms. These patients may have psychi-
atric symptoms that were masked by medication use, lead-
ing to decreased reporting of symptoms on the psychiatric
inventories. Furthermore, we cannot draw conclusions
about differential rates of psychiatric diagnosis between the
groups due to the exclusion criteria for the control groups.
Based upon the discrepancies in psychiatric evaluation,
parent-report and self-report psychiatric symptoms are
clearly complicated in WFS, and it may be difficult to dis-
tinguish what symptoms are related to pathological WFS
versus symptoms related to having a severe chronic and de-
generative illness with multisensory system effects. Future
studies on psychiatric illness in WFS could explore different
self-report measures than the ones used in the current
study. Nonetheless, these findings indicate that some psy-
chiatric symptoms may be manageable in WFS patients
with typical pharmacologic treatments.
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Conclusion
The results of this study indicate that cognitive per-
formance and self- and parent-reported psychiatric
symptoms are not different from controls in the early
stages of WFS, while smell and sleep abnormalities
manifest throughout the age range. This pattern may
differ over time, as neurodegenerative processes con-
tinue, and thus, in later stages of the disease cognitive
and psychiatric symptoms may play a larger role in
WFS. Although self-reported psychiatric measures and
clinical evaluations yielded incongruent results, at the
present time, patients did not report significant impair-
ment from active psychiatric symptoms. Given the po-
tential impact of all of these domains on quality of life,
symptomatic treatments (e.g. anti-depressants) and in-
terventions for the fundamental neurodegenerative
process are of great interest. Longitudinal assessments
of these domains are currently underway, which will
clarify whether cognitive and psychiatric disorders are
later emerging problems in WFS and will identify mea-
sures that might serve as biomarkers of disease pro-
gression for use in future clinical trials.
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